LEXINGTON, Mass. — August 6, 2025 — Leads & Copy — Keros Therapeutics, Inc. (Nasdaq: KROS) is discontinuing development of cibotercept (KER-012) and announcing board and leadership changes to support a streamlined operational structure and strategic realignment. The company will focus on advancing KER-065, a key clinical program.
The decision to halt cibotercept’s development follows the termination of its development in pulmonary arterial hypertension (PAH) after analyzing data from the TROPOS Phase 2 clinical trial in patients with PAH, previously announced on May 29, 2025.
Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros Therapeutics, stated the company is committed to delivering value for stockholders and patients by streamlining operations and focusing exclusively on advancing KER-065 for individuals living with Duchenne muscular dystrophy (DMD).
Keros announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers, achieving key objectives for safety, tolerability, pharmacokinetics, and pharmacodynamics. The company plans to initiate a Phase 2 clinical trial of KER-065 in patients with DMD in the first quarter of 2026, pending positive regulatory interaction.
Leadership changes include Jasbir S. Seehra, Ph.D., assuming the additional role of President, effective August 18, 2025. Jean-Jacques Bienaimé has been appointed as Chair of the Board, effective August 18, 2025. Christopher Rovaldi will cease employment with Keros, effective August 18, 2025. Lorena Lerner, Ph.D., is being promoted to Chief Scientific Officer, effective August 6, 2025.
Investor Contact: Justin Frantz, jfrantz@kerostx.com, 617-221-6042. Media Contact: Mahmoud Siddig / Adam Pollack / Viveca Tress, Joele Frank, Wilkinson Brimmer Katcher, (212) 355-4449.
Source: Keros Therapeutics, Inc.
